drugset / Trial / NCT06732258
Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the tolerability and safety of Low-dose radiotherapy combined with concurrent Chemotherapy, Toripalimab and Tifcemalimab in first-line treatment of Extensive-Stage Small Cell Lung Cancer, and to determine the RP2D.
Timeline
- Start
- 2025-01-10
- Primary completion
- 2026-02-28
- Completion
- 2028-02-29
Outcome
Outcome not reported
Stopped: “Inorder to avoid the serious adverse effect of Toripalimab combining with Tifcemalimab, considering as the protection of participants.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tifcemalimab | Monoclonal antibody | 100 mg | — |
| Subject | Tifcemalimab | Monoclonal antibody | 200 mg | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |
| Background | Toripalimab | Monoclonal antibody | 240 mg | — |